Skip to content Skip to navigation

Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy.

TitlePharmacokinetics of oral valacyclovir and acyclovir in late pregnancy.
Publication TypeJournal Article
Year of Publication1998
AuthorsKimberlin DF, Weller S, Whitley RJ, Andrews WW, Hauth JC, Lakeman F, Miller G
JournalAm J Obstet Gynecol
Volume179
Issue4
Pagination846-51
Date Published1998 Oct
ISSN0002-9378
KeywordsAcyclovir, Adult, Antiviral Agents, Double-Blind Method, Female, Gestational Age, Herpes Genitalis, Herpesvirus 2, Human, Humans, Pregnancy, Pregnancy Complications, Infectious, Prospective Studies, Recurrence, Valine
Abstract

<p><b>OBJECTIVE: </b>The objective was to obtain preliminary pharmacokinetic data for acyclovir from gravid women receiving herpes simplex virus suppressive therapy with the acyclovir prodrug valacyclovir.</p><p><b>STUDY DESIGN: </b>In a prospective, double-blind trial, 20 women with a history of recurrent genital herpes simplex virus infection and positive herpes simplex virus 2 serologic results were randomly assigned at 36 weeks' gestation to receive oral valacyclovir (500 mg twice daily) or acyclovir (400 mg 3 times daily). Acyclovir pharmacokinetic profiles were obtained after the initial dose (36 weeks) and at steady state (38 weeks). Amniotic fluid samples were obtained during labor and simultaneous umbilical cord and maternal plasma samples were collected at delivery. Laboratory studies were performed to screen for laboratory evidence of toxicity in mothers and infants.</p><p><b>RESULTS: </b>Peak acyclovir plasma concentrations (mean +/- standard deviation) were higher in valacyclovir recipients than in acyclovir recipients after the initial dose (3.14 +/- 0.7 microg/mL vs 0.74 +/- 0.6 microg/mL, P < .0001) and at steady state (3.03 +/- 1.0 microg/mL vs 0.94 +/- 0.7 microg/mL, P < .001). The daily area under the curve values were higher in valacyclovir recipients than acyclovir recipients after the initial dose (17.8 +/- 3.6 h x microg/mL vs 7.71 +/- 2.5 h x microg/mL, P < .001) and at steady state (19.65 +/- 6.4 h x microg/mL versus 11.0 +/- 4.5 h x microg/mL, P = .009). There was no significant difference in drug elimination half-life or in time to peak concentration between valacyclovir and acyclovir recipients at either sampling interval. Acyclovir was concentrated in the amniotic fluid; however, there was no evidence of preferential fetal drug accumulation (mean maternal/umbilical vein plasma ratios at delivery were 1.7 for valacyclovir and 1.3 for acyclovir). Valacyclovir was well tolerated, and no significant laboratory or clinical evidence of toxicity was detected.</p><p><b>CONCLUSION: </b>In this phase I trial maternal valacyclovir therapy resulted in higher plasma acyclovir levels, with significantly higher peak concentrations and daily area under the curve values, than did acyclovir therapy. Additional trials are needed to further evaluate the safety and efficacy of suppressive valacyclovir therapy during late pregnancy.</p>

Alternate JournalAm. J. Obstet. Gynecol.
Citation KeyCK108
PubMed ID9790357